Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.

Inclusion Criteria

• Patients with an age of ≥ 18 and ≤ 80 years

• Diagnosis of CAP or HAP requiring hospitalization

• Patients with one of the following :

• At least one cardiovascular comorbidity:

• Chronic atrial fibrillation

• History of ischemic heart disease (≥ 3 months)

• Heart failure

• Cardiac Valvular Disease

• Previous (≥ 6 months) episode of myocarditis or pericarditis.

• Very high risk of developing cardiovascular diseases according to the SCORE2 and SCORE2-OP risk models for moderate risk European regions (score ≥ 7.5% for patients < 50 years old, score ≥ 10% for patients 50-69 years old, and score ≥ 15% for patients ≥ 70 years old).

• Provision of written informed consent as approved by the Ethics Committee (EC).

Exclusion Criteria

Medical Conditions:

• Active malignancy

• Severe heart failure (NYHA class III and IV)

• End-stage renal failure (eGFR < 30 mL/min)

• Severe liver disease

• History of hypersensitivity to glutathione or any excipients

• Use of drugs containing sacubitril

• Use of drugs with antioxidant activity in the last 3 months

• Use of narcotics

• Use of invasive mechanical ventilation

• Recent (< 3 months) ACS (STEMI, NSTEMI, UA), myocardial revascularization, myocarditis, acute pericarditis episodes.

General Conditions:

• Pregnant or breastfeeding women

• Women of child-bearing potential not using at least one effective contraceptive method for the entire trial

• Participation in other investigational drug or device clinical trials within 30 days prior to study screening

• Patients legally or mentally incapacitated unable to give informed consent for the participation in this trial

• Patients unable or unwilling to comply with the appointments after hospitalization or with all the requirements of the Protocol.